KeyBanc Starts Livanova (LIVN) at Overweight

KeyBanc analyst Brett Fishbin initiates coverage on Livanova (NASDAQ: LIVN) with a Overweight rating and a price target of $81.00.

The analyst comments: "We believe LIVN is in the midst of an underappreciated performance inflection, and see multiple sources of potential upside vs. expectations. More specifically: 1) LIVN's MSD-HSD 2025-2028 growth outlook appears conservative, given drivers such as an ongoing HLM capital cycle, share gains in CP Consumables, and improved clinical data/reimbursement in DRE; 2) we anticipate continued progress toward the commercialization of new platforms, notably aura6000 in OSA, which are likely to expand LIVN's TAM; and 3) LT, we see a credible pathway for improved margins once it leverages growth investments."

For an analyst ratings summary and ratings history on Livanova click here. For more ratings news on Livanova click here.

Shares of Livanova closed at $62.08 yesterday.

You May Also Be Interested In

• CleanSpark (NASDAQ: CLSK) spike attributed to vague unsourced unconfirmed chatter making rounds
• Abbott study finds diabetic ketoacidosis often goes unrecognized
• Marvell Technology and Flex to join S&P 500; others to join S&P MidCap 400 and S&P SmallCap 600